|
Indian Journal of Pharmacology
Medknow Publications on behalf of Indian Pharmacological Society
ISSN: 0253-7613 EISSN: 1998-3751
Vol. 36, Num. 5, 2004, pp. 332-332
|
Indian Journal of Pharmacology, Vol. 36, No. 5, October, 2004, pp. 332
Molecules of the Millennium
Tirapazamine and gene-directed enzyme prodrug therapy of cancer
Rahman Taufiq-Ur
School of Biological Sciences, The University of Manchester, G.250 Stopford Building, M13 9PL, Oxford Road, Manchester
Correspondence Address:School of Biological Sciences, The University
of Manchester, G.250 Stopford Building, M13 9PL, Oxford Road, Manchester
m.t.rahman@stud.man.ac.uk
Code Number: ph04118
Gene-directed enzyme prodrug therapy (GDEPT) is a suicide gene therapy approach where the delivered gene encodes an enzyme that activates a prodrug administered systemically. The prodrug is non-toxic per se but begets an active metabolite due to action of the expressed enzyme. As an anticancer strategy, GDEPT couples chemotherapy with gene therapy and offers immense therapeutic potential with more tumor specificity and less systemic toxicity. Another additional benefit of such an approach is the bystander effect by which the active cytotoxic metabolite diffuses into neighboring, non-transfected tumor cells and kills/radiosensitizes them.
Most solid tumors have a hypoxic population of cells that are both chemo
and radio-resistant. Such a hypoxic microenvironment of the tumor can
be exploited therapeutically by using the bioreductive prodrug in the
GDEPT approach where the gene expresses the prodrug-activating enzyme
preferentially in hypoxic cells of solid tumors. One prominent example
of bioreductive prodrug is tirapazamine (TPZ or SR 4233). Chemically,
tirapazamine is 1, 2, 4-benzotriazin-3-amine 1, 4-dioxide, which becomes
activated by NADPH: cytochrome 450 reductase (P450R), to give cytotoxic
metabolites, mainly its 1-N-oxide (SR 4317). Both, generating free radicals
and oxidizing these radicals to cause DNA strand breaks have been suggested
as the possible mechanism of action of TPZ.
The hypoxia-regulated GDEPT using TPZ exploits the anaerobic activation
of hypoxia inducible factor (HIF-1) - a transcription factor that binds
to hypoxia response element (HRE) of genes encoding proteins (e.g.
GLUT-1, VEGF and enzymes of anaerobic glycolytic pathway) that help tissues
cope
with hypoxia in various ways. To bio-activate TPZ, the expression of
P450R is placed under the transcriptional control of HIF-1 through
the use of hypoxia response element (HRE) in the expression cassette.
The
gene construct is finally delivered to the target tissues mainly via
adenovirus.
Preclinical studies of TPZ have demonstrated its ability to potentiate
the antitumor effect of radiotherapy and chemotherapy significantly,
in particular, platinum-based drugs (e.g. cisplatin) and taxanes,
in both murine and human xenograft models. This encouraging data has
initiated
Phase I, II, and III trials with TPZ in combination with cisplatin
for the treatment of solid tumors including non-small cell lung cancer,
breast
cancer, head and neck cancer, and melanoma and as an adjuvant to
radiotherapy in Phase II trials for head and neck cancer, cervical cancer
and glioblastoma
multiforme.
Phase III trials using cisplatin and TPZ for the treatment of advanced
non-small cell lung cancer demonstrated a significant survival
benefit for patients treated with the combined regimen showing a doubling
in response rate compared with patients treated with cisplatin
alone.
A partial beneficial response of TPZ/P450R has also been found
in breast
carcinoma in Phase I clinical trial. Recently, the Stratford group
at
the University of Manchester has found complete tumor regression
using TPZ in a human tumor model (HT 1080 fibrosarcoma) transfected
with
adenoviral construct containing P450R gene. Thus hypoxia-regulated
GDEPT using tirapazamine
provides an optimistic, tempting approach for treating solid malignant
tumor with more specificity and less toxicity in future.
Copyright 2004 - Indian Journal of Pharmacology
|